Focusing on donor characteristics and efficient selection to improve allogeneic cell therapy outcomes
Sponsor
As the next generation of therapies are developed, HLA matching will play an important role for a number of leading-edge therapeutics, including allogeneic cellular therapies.
As the importance of HLA grows in relation to the development of new therapies, one of our primary objectives at Be The Match BioTherapies® is utilizing our amassed historical data to develop search and matching algorithms to ensure patients receive the therapies with the greatest probability of success. Understanding how HLA matching components will impact cell bank set-ups and population coverage is a necessity for any organization with an emerging therapy in its pipeline.
Attend this webinar for an in-depth presentation from Martin Maiers, MS, Vice President of Biomedical Informatics at our research partner, the CIBMTR®, and a live Q&A featuring well-known industry professionals.
As a webinar attendee, you will learn about:
- What to expect when scaling your volume and how that can impact cell banking processes
- How to navigate, and ultimately reduce, the uncertainties associated with HLA matching as you develop new allogeneic cellular therapies
- How access to a large, diverse starting donor pool can help you minimize your risk in obtaining high-quality, therapy-matched material
- How to create efficiencies for donor selection through emerging tools and Be The Match’s large datasets, in order to maximize population coverage and improve therapy efficacy
SPEAKERS
You might also like
The role of AI in predicting stem cell donor availability
Optimizing access to high quality, standardized, and compliant leukopaks for the development and commercialization of allogeneic therapies
Enhancing CAR-T therapy development: harnessing cell selection flexibility
Can primary packaging selection help mitigate particulate risks in cell and gene therapy manufacturing?
